Sleep Disturbance in Advanced CancerSWANNCT07068971
Sleep Well At Night
A study testing Online cognitive behavioural therapy for insomnia, bright light therapy, activity in people with Sleep Disturbance in Advanced Cancer, run by Our Lady's Hospice and Care Services at 1 site in Ireland.
Trial summary
Research has shown that the incidence of sleep disturbances in people with cancer is much higher than in the general population. Sleep problems can lead to worse symptoms, quality of life, and potentially impact outcomes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sleep Disturbance in Advanced Cancer
- What is being tested?
- Online cognitive behavioural therapy for insomnia, bright light therapy, activity
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteIreland
- Study dates
- 19 Aug 2024to 24 Aug 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years old and over
- Diagnosis of advanced cancer (locally advanced, metastatic)
- Subjective sleep disturbance
- Total score of 5 or more on PSQI
- Eastern Cooperative Oncology Group (ECOG) performance status 1-3
- Attending outpatients (oncology and/or palliative care)
- Estimated prognosis of > 3 months
Who cannot join
- Inpatient
- ECOG performance status 4
- Cognitive impairment limiting the ability to complete assessment tools and sleep diary
- Engaged in shift work
- A recent exacerbation of symptoms (e.g. pain/nausea/dyspnoea) which may impact sleep
- History of uncontrolled mania or bipolar disorder
- Recent history or current thoughts of self-harm or suicide
- Recent change in antidepressant medication
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Assessing the Feasibility of a Multi-modal Intervention for Sleep Disturbances in Patients With Advanced Cancer
Research has shown that the incidence of sleep disturbances in people with cancer is much higher than in the general population. Sleep problems can lead to worse symptoms, quality of life, and potentially impact outcomes. The most common treatment of sleep disturbances is medication which often comes with unwanted side-effects and risk. This study aims to test whether a non-drug intervention can be given to people with cancer to help with sleep disturbances.
The study will take place over 8-weeks. The first and final week of the study involves assessments (further described below) while the intervention will take place over weeks 2-7. The intervention involves an online cognitive behavioural therapy course, daily bright light therapy and engaging with an activity plan.
Read more
The initial review aims to identify any reversible causes of the sleep disturbance, including reviewing uncontrolled symptoms and medications.
Cognitive behavioural therapy for insomnia (CBT-I) has been shown to be effective at improving the time it takes for people to fall asleep and reducing the amount of time you wake up in the night.
Light therapy mimics our natural exposure to sunlight. Light exposure may help to improve sleep during the night, mood, and activity or attention levels during the day.
Physical activity levels will also be reviewed. Interests and barriers to activity will be discussed and goals will be set for activity. This will be reviewed weekly.
Questionnaires will be completed in the first and final week of the study to assess sleep, symptoms and quality of life. Wrist actigraphy, thigh accelerometry and a sleep diary will also be used on the first and final week of the study to assess sleep, activity and subjective sleep patterns.
Read the detailed description
Advances in cancer treatments have improved prognosis for many patients, placing a heightened demand on clinical care to provide quality of life as well as quantity of life. Individuals with advanced cancer face progressive symptoms that are a major source of suffering and impairment. Sleep disturbance is a prevalent, but often overlooked symptom, affecting up to 96% of patients with advanced cancer. While there are multiple types of sleep disorders affecting patients with advanced cancer, insomnia seems to be the most prevalent sleep disorder in this patient cohort, occurring at various points in the patient's disease and treatment trajectory. Adequate sleep is essential for maintaining normal function and overall existence. Inadequate sleep may further compound illness and impair recovery. Sleep disturbances are associated with fatigue, accidents/injuries, anxiety and depression, cognitive impairment and delirium and immunosuppression. In addition, sleep disturbance is associated with aberrant patterns of cortisol secretion, which can impair the cellular immunity responsible for mounting a defence against tumours. Pharmacotherapy is the most common treatment for sleep disturbances, despite the numerous associated adverse effects and absence of empirical evidence of their efficacy and innocuity in this patient population. Multiple studies have recognised that patients with advanced cancer are at an increased risk of harm induced by medications due to age, polypharmacy and co-morbidities that can alter pharmacodynamics. Yet, despite the evidence of harmful effects of hypnotics and the lack of evidence to support their use, they are routinely prescribed as first-line treatment for the management of sleep disturbances in patients with advanced cancer.
Cognitive behavioural therapy for insomnia (CBT-I) is considered the non-pharmacological first-line treatment to manage insomnia in adults. CBT for insomnia includes various components that helps the patient to learn coping skills and ways to prevent or mitigate the severity of future episodes.
Both bright white light therapy and exercise have proven to be successful non-pharmacological methods of optimising daytime activity, improving sleep duration and enhancing symptoms and quality of life in patients with cancer.
Study interventions
- CBT-I is a first-line treatment for insomnia. The online course consists of four CBT-I sessions and allows the individual to complete one module per week in the comfort of their own home. Online CBT-I has been shown to be as effective as face-to-face CBTI. CBT-I covers cognitive and behavioural aspects to understand sleep processes and improve sleep duration and quality.
- Bright light therapy has been shown to be effective at improving night-time sleep and daytime physical activity. It is delivered from a light box. The participants will be advised to sit near the light box for 30 minutes each morning. Participants can continue with other activities, such as eating breakfast, whilst sitting with the light box.
- An individualised physical activity plan will be created to encourage increased daytime physical activity and reduced daytime sedentary behaviour. Existing physical activity levels will be considered, any barriers to physical activity addressed, and goals for physical activity set. These will be reviewed on a weekly basis and adjusted as appropriate. For example, if goals are easily being achieved, further activity increases will be advised. If the patient struggles to meet goals, their goal will be lowered. Patients will be provided with a generic watch activity tracker to help them to monitor their progress.
Study Duration/ Study Timeline:
All participants will receive the intervention over an 8-week period. Where possible, participants baseline and repeat assessments will be arranged to avoid assessments taking place during a week of intravenous systemic anticancer therapy as this may impact symptoms and results.
At baseline, participants will complete three questionnaires related to symptoms, sleep disturbance and quality of life. Participants will be given a Polar Unite watch to wear for the duration of the study (8 weeks) as a primary objective measure for the purpose of measuring sleep and activity. Participants will also complete a sleep diary during the first week and wear a thigh accelerometer as a secondary objective outcome to measure activity including time spent lying, sitting, standing and stepping.
At the end of week one, participants will return the sleep diary and thigh accelerometer and they will be provided with and educated on the use of the bright white light box and the CBT-I platform. An individualised activity plan will be created between the research team and the participant. Participants will receive 6 weeks of the intervention prior to a final week where they repeat the questionnaires, thigh accelerometer and diary completion. Weekly virtual contacts will take place throughout the intervention. These will consider adverse events, technical complications, to advise on adjustments to the activity plan and to encourage engagement with the intervention.
Baseline - beginning of week one Participants will attend to meet the researcher at a convenient location. The initial clinical review is expected to take approximately 60 minutes. A checklist will be used throughout to ensure all steps are completed. The participant will be provided with a Polar Unite watch, a thigh accelerometery device and a sleep diary. The participant will wear the Polar Unite watch for the duration of the study (8 weeks). They will wear the thigh accelerometer device for 3 days and 3 nights (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays) of the first week to capture their baseline activity and for 3 days and 3 nights (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays) of the final week (post-intervention). The thigh accelerometer and sleep diary will be returned/collected on Friday (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays) of the same week and at this point the patient will begin to receive the intervention (CBT-I, bright white light therapy and their activity plan).
The baseline assessment may highlight physical/psychological symptoms abnormalities. In this event, and with the patient's verbal consent, the clinical team (GP, oncologist, palliative physician) will be made aware of the findings to review further.
The consent form and baseline assessments will be completed to include:
- Demographics: Age, sex, race, living situation, bedroom situation, sleep posture.
- Clinical history: cancer history (date of diagnosis, type of cancer, stage of cancer and current oncology treatment, past medical history, medication).
- Lifestyle: smoking history, caffeinated drink use, alcohol use, daily activity.
- The following assessment tools; PSQI MSAS-SF EORTC QLQ-C15-PAL Dreams \& Nightmares Questionnaire
End of week one The researcher will meet with the participant again on Friday of week one (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays). This meeting will focus on an introduction to the interventions and the rationale behind them, including CBT-I and bright white light therapy. It will also involve a discussion around personal interests, barriers to activity, and goals to improve activity levels throughout the day.
Weeks 2-7 - Ongoing intervention Virtual contacts will occur over the phone. The research team will assess for any technical challenges. Goals will be recalled and engagement in the intervention encouraged and any barriers will be addressed.
Week 8 - Completion of intervention and repeat monitoring The researcher will meet with the participant on Monday (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays) and repeat the assessment tools (PSQI, MSAS-SF, EORTC QLQ-C15-PAL). The thigh accelerometer and sleep diary will be repeated again for 3 days and 3 nights and returned/collected on the Friday (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays).
- Conditions
- Sleep Disturbance in Advanced Cancer
- Being tested
- Online cognitive behavioural therapy for insomnia, bright light therapy, activity
- Keywords
- Non-pharmacological, Multimodal, Interventional, Feasibility study, Advanced cancer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Online cognitive behavioural therapy for insomnia, bright light therapy, activityBehavioural
Multimodal intervention
| Study group | Role | What they receive |
|---|---|---|
| Receiving intervention | Experimental | Participants recruited to the study will receive the multimodal intervention as described. Receives: Behavioral: Online cognitive behavioural therapy for insomnia, bright light therapy, activity |
What is being measured
The primary outcome is the main question the study is designed to answer.
Retention rate
considering the number of patients who entered the study and completed the study.
Measured: through study completion - 8 weeks
Recruitment
considering the number of patients approached to take part in the study who then entered the study
Measured: one year
Completion of the intervention
Considering engagement with various interventions. The case report form will capture engagement with online cognitive behavioural therapy for insomnia where progress can be viewed online and the sleep diary will be reviewed. The participant will report on use of the bright light therapy box and activity levels throughout the study.
Measured: 8 weeks
Acceptability
A patient acceptability questionnaire of various aspects of the study, including interventions and study protocol, will be completed at the end of the study.
Measured: 8 weeks
Secondary outcomes (2)
Sleep quality
Using brief Pittsburgh Sleep Quality Index. A score of 5 or more indicates poor sleep question. Maximum score of 21. The higher the score, the poorer the sleep quality.
Measured: Week 8
Physical symptoms
Assessed using the Memorial Symptom Assessment Scale-Short Form. This is a 32-item tool, is a valid and reliable tool within the cancer population for assessing physical and psychological symptoms over the preceding week. Each symptom is only rated if present. This tool provides sub-scale scores rather than a total score. No "maximum score" is reported - rather average subscale scores. The higher the mean, the greater the symptom burden.
Measured: Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2025
- Study start19 Aug 2024
- Primary completion24 Aug 2025 (estimated)
- Study completion24 Aug 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sleep Disturbance in Advanced CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Our Lady's Hospice and Care Services
- Sponsor type
- University, hospital or other
- Collaborators
- St Vincent's University Hospital, Ireland
- Responsible party
- Principal investigator, Prof Andrew Davies, Our Lady's Hospice and Care Services
- Investigators
- Professor Andrew Davies, Principal investigator, Our Lady's Hospice & Care Services
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07068971
- Sponsor's protocol ID
- RS23-076
- Other IDs
- RS23-076
- Acronym
- SWAN
- Status last verified
- Jul 2025
- First submitted
- 26 Jun 2025
- Last updated
- 16 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This is a feasibility study, and thus is not sufficiently powered to provide robust evidence of the efficacy of the intervention. Data from a future definitive study will be shared with bona fide researchers subject to them signing a data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing the Feasibility of a Multi-modal Intervention for Sleep Disturbances in Patients With Advanced Cancer
- ClinicalTrials.gov ID
- NCT07068971
- Acronym / sponsor ID
- SWAN / RS23-076
- Conditions
- Sleep Disturbance in Advanced Cancer
- Keywords
- Non-pharmacological, Multimodal, Interventional, Feasibility study, Advanced cancer
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Our Lady's Hospice and Care ServicesUniversity, hospital or other
- Collaborators
- St Vincent's University Hospital, Ireland
- Study start
- 19 Aug 2024 (actual)
- Primary completion
- 24 Aug 2025 (estimated)
- Study completion
- 24 Aug 2025 (estimated)
- First posted
- 16 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Research has shown that the incidence of sleep disturbances in people with cancer is much higher than in the general population. Sleep problems can lead to worse symptoms, quality of life, and potentially impact outcomes. The most common treatment of sleep disturbances is medication which often comes with unwanted side-effects and risk. This study aims to test whether a non-drug intervention can be given to people with cancer to help with sleep disturbances.
The study will take place over 8-weeks. The first and final week of the study involves assessments (further described below) while the intervention will take place over weeks 2-7. The intervention involves an online cognitive behavioural therapy course, daily bright light therapy and engaging with an activity plan.
The initial review aims to identify any reversible causes of the sleep disturbance, including reviewing uncontrolled symptoms and medications.
Cognitive behavioural therapy for insomnia (CBT-I) has been shown to be effective at improving the time it takes for people to fall asleep and reducing the amount of time you wake up in the night.
Light therapy mimics our natural exposure to sunlight. Light exposure may help to improve sleep during the night, mood, and activity or attention levels during the day.
Physical activity levels will also be reviewed. Interests and barriers to activity will be discussed and goals will be set for activity. This will be reviewed weekly.
Questionnaires will be completed in the first and final week of the study to assess sleep, symptoms and quality of life. Wrist actigraphy, thigh accelerometry and a sleep diary will also be used on the first and final week of the study to assess sleep, activity and subjective sleep patterns.
Detailed description
Advances in cancer treatments have improved prognosis for many patients, placing a heightened demand on clinical care to provide quality of life as well as quantity of life. Individuals with advanced cancer face progressive symptoms that are a major source of suffering and impairment. Sleep disturbance is a prevalent, but often overlooked symptom, affecting up to 96% of patients with advanced cancer. While there are multiple types of sleep disorders affecting patients with advanced cancer, insomnia seems to be the most prevalent sleep disorder in this patient cohort, occurring at various points in the patient's disease and treatment trajectory. Adequate sleep is essential for maintaining normal function and overall existence. Inadequate sleep may further compound illness and impair recovery. Sleep disturbances are associated with fatigue, accidents/injuries, anxiety and depression, cognitive impairment and delirium and immunosuppression. In addition, sleep disturbance is associated with aberrant patterns of cortisol secretion, which can impair the cellular immunity responsible for mounting a defence against tumours. Pharmacotherapy is the most common treatment for sleep disturbances, despite the numerous associated adverse effects and absence of empirical evidence of their efficacy and innocuity in this patient population. Multiple studies have recognised that patients with advanced cancer are at an increased risk of harm induced by medications due to age, polypharmacy and co-morbidities that can alter pharmacodynamics. Yet, despite the evidence of harmful effects of hypnotics and the lack of evidence to support their use, they are routinely prescribed as first-line treatment for the management of sleep disturbances in patients with advanced cancer.
Cognitive behavioural therapy for insomnia (CBT-I) is considered the non-pharmacological first-line treatment to manage insomnia in adults. CBT for insomnia includes various components that helps the patient to learn coping skills and ways to prevent or mitigate the severity of future episodes.
Both bright white light therapy and exercise have proven to be successful non-pharmacological methods of optimising daytime activity, improving sleep duration and enhancing symptoms and quality of life in patients with cancer.
Study interventions
- CBT-I is a first-line treatment for insomnia. The online course consists of four CBT-I sessions and allows the individual to complete one module per week in the comfort of their own home. Online CBT-I has been shown to be as effective as face-to-face CBTI. CBT-I covers cognitive and behavioural aspects to understand sleep processes and improve sleep duration and quality.
- Bright light therapy has been shown to be effective at improving night-time sleep and daytime physical activity. It is delivered from a light box. The participants will be advised to sit near the light box for 30 minutes each morning. Participants can continue with other activities, such as eating breakfast, whilst sitting with the light box.
- An individualised physical activity plan will be created to encourage increased daytime physical activity and reduced daytime sedentary behaviour. Existing physical activity levels will be considered, any barriers to physical activity addressed, and goals for physical activity set. These will be reviewed on a weekly basis and adjusted as appropriate. For example, if goals are easily being achieved, further activity increases will be advised. If the patient struggles to meet goals, their goal will be lowered. Patients will be provided with a generic watch activity tracker to help them to monitor their progress.
Study Duration/ Study Timeline:
All participants will receive the intervention over an 8-week period. Where possible, participants baseline and repeat assessments will be arranged to avoid assessments taking place during a week of intravenous systemic anticancer therapy as this may impact symptoms and results.
At baseline, participants will complete three questionnaires related to symptoms, sleep disturbance and quality of life. Participants will be given a Polar Unite watch to wear for the duration of the study (8 weeks) as a primary objective measure for the purpose of measuring sleep and activity. Participants will also complete a sleep diary during the first week and wear a thigh accelerometer as a secondary objective outcome to measure activity including time spent lying, sitting, standing and stepping.
At the end of week one, participants will return the sleep diary and thigh accelerometer and they will be provided with and educated on the use of the bright white light box and the CBT-I platform. An individualised activity plan will be created between the research team and the participant. Participants will receive 6 weeks of the intervention prior to a final week where they repeat the questionnaires, thigh accelerometer and diary completion. Weekly virtual contacts will take place throughout the intervention. These will consider adverse events, technical complications, to advise on adjustments to the activity plan and to encourage engagement with the intervention.
Baseline - beginning of week one Participants will attend to meet the researcher at a convenient location. The initial clinical review is expected to take approximately 60 minutes. A checklist will be used throughout to ensure all steps are completed. The participant will be provided with a Polar Unite watch, a thigh accelerometery device and a sleep diary. The participant will wear the Polar Unite watch for the duration of the study (8 weeks). They will wear the thigh accelerometer device for 3 days and 3 nights (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays) of the first week to capture their baseline activity and for 3 days and 3 nights (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays) of the final week (post-intervention). The thigh accelerometer and sleep diary will be returned/collected on Friday (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays) of the same week and at this point the patient will begin to receive the intervention (CBT-I, bright white light therapy and their activity plan).
The baseline assessment may highlight physical/psychological symptoms abnormalities. In this event, and with the patient's verbal consent, the clinical team (GP, oncologist, palliative physician) will be made aware of the findings to review further.
The consent form and baseline assessments will be completed to include:
- Demographics: Age, sex, race, living situation, bedroom situation, sleep posture.
- Clinical history: cancer history (date of diagnosis, type of cancer, stage of cancer and current oncology treatment, past medical history, medication).
- Lifestyle: smoking history, caffeinated drink use, alcohol use, daily activity.
- The following assessment tools; PSQI MSAS-SF EORTC QLQ-C15-PAL Dreams \& Nightmares Questionnaire
End of week one The researcher will meet with the participant again on Friday of week one (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays). This meeting will focus on an introduction to the interventions and the rationale behind them, including CBT-I and bright white light therapy. It will also involve a discussion around personal interests, barriers to activity, and goals to improve activity levels throughout the day.
Weeks 2-7 - Ongoing intervention Virtual contacts will occur over the phone. The research team will assess for any technical challenges. Goals will be recalled and engagement in the intervention encouraged and any barriers will be addressed.
Week 8 - Completion of intervention and repeat monitoring The researcher will meet with the participant on Monday (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays) and repeat the assessment tools (PSQI, MSAS-SF, EORTC QLQ-C15-PAL). The thigh accelerometer and sleep diary will be repeated again for 3 days and 3 nights and returned/collected on the Friday (+/- 3 days and 3 nights to allow for flexibility in the case of clashing appointments/bank holidays).
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Receiving intervention | Experimental | Behavioral: Online cognitive behavioural therapy for insomnia, bright light therapy, activityParticipants recruited to the study will receive the multimodal intervention as described. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- 18 years old and over
- Diagnosis of advanced cancer (locally advanced, metastatic)
- Subjective sleep disturbance
- Total score of 5 or more on PSQI
- Eastern Cooperative Oncology Group (ECOG) performance status 1-3
Key exclusion criteria (8 listed)
- Inpatient
- ECOG performance status 4
- Cognitive impairment limiting the ability to complete assessment tools and sleep diary
- Engaged in shift work
- A recent exacerbation of symptoms (e.g. pain/nausea/dyspnoea) which may impact sleep
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Online cognitive behavioural therapy for insomnia, bright light therapy, activityMultimodal intervention | Behavioural | Receiving intervention |
Primary outcome
Retention rate
Time frame: through study completion - 8 weeks
considering the number of patients who entered the study and completed the study.
Recruitment
Time frame: one year
considering the number of patients approached to take part in the study who then entered the study
Completion of the intervention
Time frame: 8 weeks
Considering engagement with various interventions. The case report form will capture engagement with online cognitive behavioural therapy for insomnia where progress can be viewed online and the sleep diary will be reviewed. The participant will report on use of the bright light therapy box and activity levels throughout the study.
Acceptability
Time frame: 8 weeks
A patient acceptability questionnaire of various aspects of the study, including interventions and study protocol, will be completed at the end of the study.
2 secondary outcomes
Sleep quality
Time frame: Week 8
Physical symptoms
Time frame: Week 8
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2025.
- Individual participant dataSharing planned: No. This is a feasibility study, and thus is not sufficiently powered to provide robust evidence of the efficacy of the intervention. Data from a future definitive study will be shared with bona fide researchers subject to them signing a data sharing agreement.
Related trials for Sleep Disturbance in Advanced Cancer
Active, not recruitingPhase 2/3
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
Sleep, Fatigue
Not yet recruitingPhase 2
Low-Frequency rTMS for In-Hospital Sleep Disturbance in Advanced NSCLC
Carcinoma, Non-Small-Cell Lung, Sleep Wake Disorders
Active, not recruitingPhase 2
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
Advanced Cancer, Anorexia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Professor Andrew Davies principal investigator
Our Lady's Hospice & Care Services
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Online cognitive behavioural therapy for insomnia, bright light therapy, activity in people with Sleep Disturbance in Advanced Cancer, run by Our Lady's Hospice and Care Services at 1 site in Ireland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 16 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Retention rate (time frame: through study completion - 8 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2025.